Saturday 17 October 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
0.98
0.02
−2.00%
Follow HOWL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (119.86%) | (161.89%) | (123.88%) | (122.43%) |
+8 more TTM periods Free account |
|
| (59.31%) | (68.09%) | (61.96%) | (66.32%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(212.45%) | (387.90%) | (224.22%) | (130.87%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(0.61) | (1.07) | (1.31) | (1.39) | |
Free Cash Flow |
(29.87) | (51.94) | (60.29) | (63.52) | |
Capital Expenditures |
0.27 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(78.05%) | (88.56%) | (73.66%) | (54.30%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
134.95% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
79.34% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
15.56% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(6.87) | (10.40) | (11.50) | (13.85) | |
Operating CF/Net income |
0.87 | 0.92 | 0.99 | 0.87 | |
Depreciation/Fixed assets |
2.89 | 0.37 | 0.35 | 0.33 | |
Capex/Depreciation |
0.07 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.50 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.62) | (1.07) | (1.31) | (1.39) | |
Capex per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | — | — | — |
Columns are period end dates